Cognito Therapeutics to Present New Data on Spectris'™ Impact on Brain Structure in Alzheimer's Disease at AD/PD 2025
CAMBRIDGE, Mass., March 25, 2025--(BUSINESS WIRE)--Cognito Therapeutics, a pioneering neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, today announced it will present new clinical data from its OVERTURE study at the AD/PD™ 2025 International Conference on Alzheimer's and Parkinson's Diseases, taking place April 1-5, 2025, in Vienna, Austria.
The presentations highlight new data from participants on Spectris™, an investigational gamma sensory stimulation therapy, demonstrating its potential to modulate brain function, preserve structural integrity, and slow neurodegeneration in Alzheimer's disease (AD).
"We are excited to share this compelling new data at AD/PD 2025, reinforcing Spectris™ as a potential disease-modifying intervention," said Christian Howell, CEO of Cognito Therapeutics. "The findings build on our previous research, showing that preserving brain connectivity and structure through non-invasive neuromodulation could significantly impact disease progression in Alzheimer's patients."
Poster Presentation Details:
Sensory Evoked Gamma Oscillation Correlates with Brain Morphology in Alzheimer's DiseaseDate/Time: Wednesday, April 2, 8:00 - 10:00 am CETPresenter: Mihaly Hajos PhD, Scientific Advisor, Cognito Therapeutics
Spectris™ Treatment Preserves Corpus Callosum Integrity in Alzheimer's Disease: A Comparative StudyDate/Time: Wednesday, April 2, 8:00 - 10:00 am CETPresenter: Ralph Kern, M.D., MHSc, Chief Medical Officer, Cognito Therapeutics
"These new data further support Spectris™ as a potential disease-modifying therapy for Alzheimer's," said Ralph Kern, M.D., MHSc, Chief Medical Officer, Cognito Therapeutics. "Our posters at AD/PD 2025 show that Spectris™ preserves corpus callosum integrity, which is critical for cognitive function, and that gamma stimulation correlates with brain structure. Together, these findings reinforce our approach to non-invasive neuromodulation and its potential to slow neurodegeneration. We look forward to validating these results in our ongoing HOPE trial."
For more information about the AD/PD 2025 conference, visit: https://adpd.kenes.com.
About Cognito Therapeutics
Cognito Therapeutics is a late-stage clinical neurotechnology company pioneering disease-modifying treatments for neurodegenerative diseases. Its lead product, Spectris™, uses non-invasive auditory and visual neuromodulation to enhance gamma frequency brain activity, with the goal of slowing brain atrophy and functional decline in Alzheimer's disease. Cognito is committed to developing transformative, technology-driven interventions to address unmet needs in the treatment of CNS diseases. Cognito is headquartered in Cambridge, MA. For more information, visit www.cognitotx.com and follow @cognitotx.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250325928392/en/
Contacts
Media Contact: Kimberly HaKKH Advisors917-291-5744Kimberly.ha@kkhadvisors.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Innovaccer Announces Availability of Innovaccer Gravity™ in the New AWS Marketplace AI Agents and Tools Category
SAN FRANCISCO, July 16, 2025--(BUSINESS WIRE)--Innovaccer Inc., a leading Healthcare AI company, today announced the availability of Innovaccer Gravity™, its Healthcare Intelligence Platform in the new AI Agents and Tools category in AWS Marketplace. This enables AWS customers to easily discover, buy, and deploy Innovaccer's Healthcare Intelligence Platform using their AWS accounts, accelerating AI agent and agentic workflow development. The AI Agents and Tools category in AWS Marketplace serves as a centralized catalog for hundreds of AI solutions from trusted AWS Partners. Gravity helps organizations activate enterprise intelligence across healthcare domains, accelerate time to value, and reduce total cost of ownership, enabling customers to modernize their AI infrastructure and deploy AI-powered solutions with ease. "By offering Gravity through the AWS Marketplace AI Agents and Tools category, we're providing customers with a streamlined way to access our Healthcare Intelligence Platform, helping them buy and deploy AI agent solutions faster and more efficiently," said Abhinav Shashank, CEO at Innovaccer. "Our customers in health systems are already using these capabilities to reduce costs, improve outcomes, and accelerate innovation, demonstrating the real-world value of Gravity." Innovaccer Gravity™ delivers essential capabilities including: Rich healthcare context including data quality rules, pre-built analytics, and end-point workflows Security and guardrails required to build and deploy AI solutions Developer Studio to rapidly build, customize, and deploy AI-powered workflows These features enable customers to unify enterprise-wide data, activate real-time insights, and activate scalable AI solutions to improve outcomes. Through the AWS Marketplace AI Agents and Tools category, customers can significantly accelerate their procurement process to drive AI innovation, reducing the time needed for vendor evaluations and complex negotiations. With centralized purchasing using AWS accounts, customers maintain visibility and control over licensing, payments, and access through AWS. Available as a SaaS solution, Innovaccer Gravity™ supports FHIR-native protocols and healthcare model context protocol (HMCP) for streamlined agent communication. This enables customers to seamlessly connect with other AWS services and flexibly deploy across their AWS environment. To learn more about Innovaccer Gravity™ in AWS Marketplace, visit Innovaccer. To learn more about the new AI Agents and Tools category in AWS Marketplace, visit About Innovaccer Innovaccer activates the flow of healthcare data, empowering providers, payers, and government organizations to deliver intelligent and connected experiences that advance health outcomes. The Healthcare Intelligence Cloud equips every stakeholder in the patient journey to turn fragmented data into proactive, coordinated actions that elevate the quality of care and drive operational performance. Leading healthcare organizations like CommonSpirit Health, Atlantic Health, and Banner Health trust Innovaccer to integrate a system of intelligence into their existing infrastructure— extending the human touch in healthcare. For more information, visit View source version on Contacts Press Contact:Arushi AwasthiInnovaccer 415-562-2139
Associated Press
25 minutes ago
- Associated Press
Arthrex NanoScope™ System Receives Pediatric Clearance for Orthopedic, Laparoscopic Procedures
NAPLES, Fla., July 16, 2025 /PRNewswire/ -- Arthrex, a global leader in minimally invasive surgical technology, announced that it has received U.S. Food and Drug Administration (FDA) clearance to use the Arthrex NanoScope™ operative arthroscopy system for pediatric orthopedics and laparoscopy. The NanoScope system is a compact, high-resolution mobile imaging platform featuring the industry's first high-definition, chip-on-tip camera — known as the NanoNeedle Scope — engineered specifically to meet the unique anatomical and procedural needs of pediatric patients. 'This innovative and disruptive technology is transforming the way we approach diagnostic and least-invasive surgical treatments, and we are extremely proud to expand its indications to the field of pediatric orthopedics and laparoscopy,' said Arthrex President and Founder Reinhold Schmieding. The NanoScope system can be used in common pediatric cases like general knee arthroscopy, meniscal treatments, anterior cruciate ligament (ACL) reconstruction, general shoulder arthroscopy and hernia or diagnostic laparoscopy in the abdomen. The smaller scope is designed to minimize the potential risk of damaging anatomical structures upon entry along with neurovascular structures. 'FDA clearance for use of the NanoScope system in pediatric patients is an important, exciting step forward,' said J. Lee Pace, MD. 'Its smaller size makes it ideal for navigating pediatric joints while still delivering excellent image quality for routine or even more complex cases.' Most Nano arthroscopy procedures can be performed outside of a traditional operating room, such as in a physician's office or an ambulatory surgery center, offering a more convenient and flexible option for both diagnosis and treatment. Patients and doctors can also discuss anesthesia options to determine the level that best fits a particular procedure and the patient's comfort level, from local anesthesia — allowing the patient to stay awake during treatment — to twilight anesthesia, or mild sedation. This minimally invasive approach also means a smaller scar,1 less risk of infection2 and the potential for less pain, reducing the need for prescriptive pain medications.3 To learn more about Nano arthroscopy, visit For more information, downloadable multimedia assets and interview requests for subject matter experts, contact Arthrex Media Relations at [email protected]. About Arthrex Arthrex, headquartered in Naples, Florida, is a global medical device company and leader in multispecialty minimally invasive surgical technology innovation, scientific research, manufacturing and medical education. The company has pioneered the field of arthroscopy and sports medicine and develops more than 1,000 new products and related procedures annually to advance minimally invasive orthopedic surgery, trauma, spine, cardiothoracic, orthobiologics and arthroplasty innovation worldwide. Arthrex also specializes in the latest 4K multispecialty surgical visualization and OR integration technology solutions. For more information, visit Physician is a paid consultant of Arthrex, Inc. References View original content to download multimedia: SOURCE Arthrex, Inc.
Business Wire
an hour ago
- Business Wire
Treatment with Next-Generation, Liquid Embolic NeoCas
WALTHAM, Mass.--(BUSINESS WIRE)-- Arsenal Medical, a clinical-stage company developing innovative biomaterials-based devices, today announced late-breaking data from the EMBO-02 clinical study for NeoCast™, a next-generation, shear-responsive liquid embolic treatment. In EMBO-02, NeoCast was evaluated in patients with chronic subdural hematoma (cSDH), a collection of blood on the surface of the brain, using middle meningeal artery embolization (MMAe). Research presented in podium sessions at the Society of Neurointerventional Surgery (SNIS) annual meeting in Nashville, Tenn., showed that all patients met primary safety and feasibility endpoints. Separate late-breaking results demonstrated that NeoCast can be administered painlessly and resulted in rapid hematoma resorption. A total of 15 patients with cSDH have been enrolled in EMBO-02 across three sites in Australia. The initial cohort (n=10) allowed either general anesthesia or conscious sedation, while the second cohort (n=5) specified the use of conscious sedation. Highlights include: 87% of patients underwent embolization without adjunctive surgery. 100% target vessel occlusion, and no non-target embolization. There were no NeoCast-related adverse events. Cohort 1 (n=10): 60% and 90% of patients had complete hematoma resolution at 3 and 6 months, respectively. 80%+ of patients had clinical outcome measures (mRS, VAS, and Markwalder) that were improved or unchanged from baseline. Cohort 2 (n=5): MMAe with NeoCast was completed under conscious sedation. No patients reported pain during the injection or increased headache 24 hours post-embolization. 'NeoCast's unique material characteristics have translated from pre-clinical studies to the EMBO-01 first-in-human study in hypervascular brain tumors, and now to the treatment of chronic subdural hematoma in EMBO-02. Results from these studies demonstrate the potential of NeoCast to provide deep distal penetration in multiple clinical scenarios and suggest benefits in speed of hematoma resolution for patients suffering from chronic subdural hematoma,' said Lee-Anne Slater, MBBS MMed FRANZCR, Interventional Neuroradiologist at Monash Health and EMBO-02 principal investigator. 'NeoCast is truly a next-generation liquid embolic agent. The ease of use, controllability, and the lack of pain during or after the injection are such differentiating factors for NeoCast over currently available liquid agents,' said Dr. Tim Phillips, MBBS GDSA FRANZCR, Interventional Neuroradiologist at the Neuro-Intervention and Imaging Service of Western Australia (NIISwa), Sir Charles Gairdner Hospital in Perth, Western Australia. 'We designed NeoCast to be a pain-free, non-adhesive biomaterial to overcome the limitations of existing liquid embolic technologies. These clinical results provide early reinforcement of what we set out to achieve, demonstrating excellent performance with an easy-to-use agent. As NeoCast continues through its robust clinical research program, we're excited about the potential impact for patients and physicians across a range of neurovascular and peripheral indications,' said Upma Sharma, CEO of Arsenal Medical. About the EMBO-02 Study The EMBO-02 study (ACTRN12624000659505) is an open-label, multicenter, prospective, externally monitored, core lab adjudicated, feasibility clinical trial. The primary safety endpoint is device-related disabling stroke or neurological death within 30 days of embolization. The primary feasibility endpoint is the successful injection of NeoCast, resulting in complete occlusion at, or distal to, the point of injection. About NeoCast™ NeoCast™ is a next-generation, solvent-free, non-adhesive liquid embolic biomaterial designed to preferentially reach distal microvasculature without inducing pain. Developed, in part, with funding from the National Cancer Institute, NeoCast leverages shear-thinning science to reach the smallest vessels and halt blood flow to tumors and injured or diseased tissues. NeoCast was designed without the use of harsh solvents and adhesives that are found in prior generation liquid embolic materials, the incorporation of which can lead to patient pain. Its unique material characteristics have been formulated to deliver enhanced control during injection. NeoCast previously demonstrated safety and feasibility in the preoperative embolization of hypervascular brain tumors in EMBO-01. About Arsenal Medical Arsenal Medical is a clinical-stage company that creates innovative biomaterials to solve challenging and underserved medical problems. Its lead products target neurovascular and trauma conditions. The company was founded by academic luminaries Robert Langer and George Whitesides, along with serial entrepreneur-investor Carmichael Roberts, who shared a vision for how materials can transform medical devices.
